vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $19.2M, roughly 1.0× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -177.4%, a 157.7% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs -11.5%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-23.1M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs -12.2%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CURI vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.0× larger
LAB
$19.6M
$19.2M
CURI
Growing faster (revenue YoY)
CURI
CURI
+47.3% gap
CURI
35.8%
-11.5%
LAB
Higher net margin
CURI
CURI
157.7% more per $
CURI
-19.7%
-177.4%
LAB
More free cash flow
CURI
CURI
$27.0M more FCF
CURI
$3.9M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CURI
CURI
Annualised
CURI
26.5%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CURI
CURI
LAB
LAB
Revenue
$19.2M
$19.6M
Net Profit
$-3.8M
$-34.7M
Gross Margin
48.5%
Operating Margin
-17.6%
-168.5%
Net Margin
-19.7%
-177.4%
Revenue YoY
35.8%
-11.5%
Net Profit YoY
-34.6%
-28.8%
EPS (diluted)
$-0.07
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
LAB
LAB
Q4 25
$19.2M
Q3 25
$18.4M
$19.6M
Q2 25
$19.0M
$21.8M
Q1 25
$15.1M
$40.8M
Q4 24
$14.1M
Q3 24
$12.6M
$22.1M
Q2 24
$12.4M
$22.5M
Q1 24
$12.0M
$45.5M
Net Profit
CURI
CURI
LAB
LAB
Q4 25
$-3.8M
Q3 25
$-3.7M
$-34.7M
Q2 25
$784.0K
$-33.5M
Q1 25
$319.0K
$-26.0M
Q4 24
$-2.8M
Q3 24
$-3.1M
$-26.9M
Q2 24
$-2.0M
$-45.7M
Q1 24
$-5.0M
$-32.2M
Gross Margin
CURI
CURI
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
CURI
CURI
LAB
LAB
Q4 25
-17.6%
Q3 25
-24.5%
-168.5%
Q2 25
2.5%
-118.1%
Q1 25
0.5%
-80.8%
Q4 24
-27.4%
Q3 24
-25.8%
-120.9%
Q2 24
-20.6%
-134.5%
Q1 24
-30.4%
-132.2%
Net Margin
CURI
CURI
LAB
LAB
Q4 25
-19.7%
Q3 25
-20.4%
-177.4%
Q2 25
4.1%
-153.7%
Q1 25
2.1%
-63.8%
Q4 24
-19.9%
Q3 24
-24.3%
-122.0%
Q2 24
-16.4%
-203.3%
Q1 24
-42.0%
-70.6%
EPS (diluted)
CURI
CURI
LAB
LAB
Q4 25
$-0.07
Q3 25
$-0.06
$-0.09
Q2 25
$0.01
$-0.09
Q1 25
$0.01
$-0.07
Q4 24
$-0.05
Q3 24
$-0.06
$-0.07
Q2 24
$-0.04
$-0.12
Q1 24
$-0.09
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$27.3M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$399.7M
Total Assets
$75.7M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
LAB
LAB
Q4 25
$27.3M
Q3 25
$27.8M
$129.4M
Q2 25
$28.1M
$158.6M
Q1 25
$33.4M
$150.9M
Q4 24
$32.1M
Q3 24
$33.2M
$210.6M
Q2 24
$39.5M
$269.8M
Q1 24
$38.8M
$287.1M
Total Debt
CURI
CURI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CURI
CURI
LAB
LAB
Q4 25
$41.5M
Q3 25
$47.2M
$399.7M
Q2 25
$49.8M
$424.5M
Q1 25
$58.1M
$454.6M
Q4 24
$57.8M
Q3 24
$62.2M
$489.3M
Q2 24
$64.8M
$510.3M
Q1 24
$67.0M
$577.3M
Total Assets
CURI
CURI
LAB
LAB
Q4 25
$75.7M
Q3 25
$74.7M
$539.6M
Q2 25
$78.7M
$557.0M
Q1 25
$85.3M
$579.6M
Q4 24
$86.2M
Q3 24
$87.6M
$681.5M
Q2 24
$90.9M
$708.7M
Q1 24
$94.6M
$777.7M
Debt / Equity
CURI
CURI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
LAB
LAB
Operating Cash FlowLast quarter
$4.0M
$-22.2M
Free Cash FlowOCF − Capex
$3.9M
$-23.1M
FCF MarginFCF / Revenue
20.5%
-118.1%
Capex IntensityCapex / Revenue
0.1%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
LAB
LAB
Q4 25
$4.0M
Q3 25
$4.4M
$-22.2M
Q2 25
$2.8M
$-20.7M
Q1 25
$1.9M
$-30.3M
Q4 24
$3.0M
Q3 24
$2.3M
$-27.9M
Q2 24
$2.2M
$-39.0M
Q1 24
$666.0K
$-62.5M
Free Cash Flow
CURI
CURI
LAB
LAB
Q4 25
$3.9M
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$1.8M
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
CURI
CURI
LAB
LAB
Q4 25
20.5%
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
12.2%
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
CURI
CURI
LAB
LAB
Q4 25
0.1%
Q3 25
0.0%
4.5%
Q2 25
0.0%
8.7%
Q1 25
0.5%
12.4%
Q4 24
0.0%
Q3 24
0.0%
10.2%
Q2 24
0.0%
8.6%
Q1 24
0.0%
1.7%
Cash Conversion
CURI
CURI
LAB
LAB
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CURI
CURI

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons